A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients-Reference-Cited by-同舟云学术

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Published:2018-07-17 Issue:11 Volume:32 Page:1431-1442
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Eron Joseph J.,Orkin Chloe,Gallant Joel,Molina Jean-Michel,Negredo Eugenia,Antinori Andrea,Mills Anthony,Reynes Jacques,Van Landuyt Erika,Lathouwers Erkki,Hufkens Veerle,Jezorwski John,Vanveggel Simon,Opsomer Magda

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference27 articles.

1. HIV treatment adherence, drug resistance, virologic failure: evolving concepts;Nachega;Infect Disord Drug Targets,2011

2. Meta-analysis of studies comparing single and multitablet fixed dose combination HIV treatment regimens;Clay;Medicine (Baltimore,2015

3. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - results from a large french multicenter cohort study;Cotte;PLoS One,2017

4. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial;Orkin;HIV Med,2013

5. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies;Lathouwers;HIV Clin Trials,2017

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of 2 Forms of Tenofovir on Duodenal Enterocytes—A Hypothesis for Different Effect of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide on Body Weight and Plasma Lipids;Clinical Infectious Diseases;2024-07-23

2. Rates of adverse events of antiretroviral therapy in women living with HIV/AIDS: a systematic review and meta-analysis;BMJ Open;2024-07

3. Antiretrovirals and Weight Change: Weighing the Evidence;Clinical Infectious Diseases;2024-04-12

4. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study;Antiviral Therapy;2024-04

5. Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure;Drug Design, Development and Therapy;2024-04